Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netoglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netoglitazone SCHEMBL29361540 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125596 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL142658 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29355957 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125595 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29355960 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL8877880 | 0.99 | FFAR1 (0.54) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| SCHEMBL7514721 | 0.89 | PTPN1 (0.52) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL4239883 | 0.89 | MAOB (0.51) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL7634850 | 0.88 | FFAR1 (0.57) | FFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024055932-A1 | AZACYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | 亚宝药业集团股份有限公司 | 2024-03-21 | — | — | WO | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |